Press Releases

Press Releases

Search by keywords:

187 Press Releases found

Antibody Therapy Prevents Gastrointestinal Damage following Radiation Exposure in Mice

A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident.

  • Wednesday, April 4, 2012

Memorial Sloan Kettering Cancer Center, IBM to Collaborate in Applying Watson Technology to Help Oncologists

Memorial Sloan Kettering and IBM have agreed to collaborate on the development of a powerful tool built upon IBM Watson to provide medical professionals with improved access to comprehensive cancer data and practices.

  • Thursday, March 22, 2012

Genetic Profiling Can Help Doctors More Accurately Predict Prognosis and Guide Treatment Decisions for Leukemia Patients

Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial Sloan Kettering Cancer Center, will be published in the March 22 issue of the New England Journal of Medicine.

  • Wednesday, March 14, 2012

Rare Medical Phenomenon Of Systemic Tumor Disappearance Following Local Radiation Treatment Reported In A Patient With Metastatic Melanoma

A rarely seen phenomenon in cancer patients — in which focused radiation to the site of one tumor is associated with the disappearance of metastatic tumors all over the body — has been reported in a patient with melanoma treated with the immunotherapeutic agent ipilimumab (Yervoy™).

  • Thursday, March 8, 2012

Colonoscopy Prevents Deaths From Colon Cancer

For the first time, a new study has shown that removing polyps by colonoscopy not only prevents colorectal cancer from developing, but also prevents deaths from the disease. Patients in the study were evaluated for up to 23 years after having the procedure, providing the longest follow-up results to date.

  • Wednesday, February 22, 2012

Cycle for Survival Event Advances Research and Treatments for Rare Cancers

More than 10,000 people nationwide will participate in Memorial Sloan Kettering Cancer Center’s sixth annual Cycle for Survival event taking place this February at Equinox clubs in New York City, Long Island, Washington D.C., Chicago, San Francisco, and Los Angeles.

  • Wednesday, February 1, 2012

Targeted Therapy Improves Overall Survival in Men with Late-Stage Prostate Cancer

The investigational oral drug MDV3100 significantly improved overall survival in patients with advanced prostate cancer, results of a large, phase III study show.

  • Tuesday, January 31, 2012

Memorial Sloan Kettering Receives $50 Million in Honor of Josie Robertson

As a tribute to Memorial Sloan Kettering Board member Josephine “Josie” Robertson, Memorial Sloan Kettering has joined with The Robertson Foundation to undertake two high-profile initiatives — the Josie Robertson Surgery Center and the Josie Robertson Investigators Program — made possible by a $50 million commitment from The Robertson Foundation.

  • Wednesday, December 21, 2011

Experimental Treatment Could Improve Stem Cell Transplants

A Memorial Sloan Kettering Cancer Center study suggests that a new, experimental treatment could make bone marrow and stem cell transplantation more effective and safe.

  • Saturday, December 10, 2011

Researchers Discover Why New Melanoma Drug Stops Working

Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug, vemurafenib.

  • Wednesday, November 23, 2011